Vancomycin Resistant Enterococcal (VRE) Infection Drug Development Pipeline Study, H2 2018

  • ID: 4604884
  • Report
  • 70 pages
  • VPA Research
1 of 4
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical Studies

FEATURED COMPANIES

  • Aphios Corporation
  • AzurRx BioPharma Inc
  • LegoChem Biosciences Inc
  • Naicons Srl
  • Oragenics Inc
  • Rebiotix Inc
  • MORE
Vancomycin Resistant Enterococcal (VRE) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Vancomycin Resistant Enterococcal (VRE) Infection pipeline products.

DISEASE OVERVIEW:

Vancomycin-resistant enterococcal infection (VRE) is a key nosocomial pathogen occurring mostly in GI tract and occasionally observed in GU tract, skin or oral cavity. High mortality rates are associated with VRE.

Enteroccocci is common bacteria observed in intestines of human and in case of any infections, it is often treated with Vancomycin. However, VRE is an emerging antibiotic resistant bacteria, that belongs to the species- Enterococcus faecalis and Enterococcus faecium, which is resistant to this drug and accordingly, named as VRE.

North American countries report high prevalence of the disease. It occurs mainly during long hospital stays, ICU, long-term care facility, person-to-person contamination etc. Further, it is also associated with certain comorbid conditions.

Amidst high prevalence of the disease in North America and increasing scope in European countries, 16 companies are currently focusing on developing pipeline products for Vancomycin-resistant enterococcal infections

The current VRE pipeline products comprise of antibiotics against the bacteria along with other drugs such as AM 218, AZX1103, BDM-I, contezolid, HB1345, LCB01-0371, Marinus, MGB-BP3, NAI-107, NAI-603, OG716, RBX2660, SLP-0901, SLP-0905, Teixobactin, WCK 5222.

REPORT DESCRIPTION:

The Vancomycin Resistant Enterococcal (VRE) Infection pipeline guide presents complete overview of drugs currently being developed for Vancomycin Resistant Enterococcal (VRE) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Vancomycin Resistant Enterococcal (VRE) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Vancomycin Resistant Enterococcal (VRE) Infection pipeline candidates is included.

Major companies participating in therapeutic development of Vancomycin Resistant Enterococcal (VRE) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Vancomycin Resistant Enterococcal (VRE) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Vancomycin Resistant Enterococcal (VRE) Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Vancomycin Resistant Enterococcal (VRE) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Vancomycin Resistant Enterococcal (VRE) Infection pipeline report includes:
  • Panorama of Vancomycin Resistant Enterococcal (VRE) Infection pipeline markets including statistics on therapeutic drugs and companies involved
  • Vancomycin Resistant Enterococcal (VRE) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
  • Vancomycin Resistant Enterococcal (VRE) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Vancomycin Resistant Enterococcal (VRE) Infection pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Vancomycin Resistant Enterococcal (VRE) Infection pipeline therapeutics
Reasons to Buy:
  • Get clear understanding of the entire Vancomycin Resistant Enterococcal (VRE) Infection pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Vancomycin Resistant Enterococcal (VRE) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aphios Corporation
  • AzurRx BioPharma Inc
  • LegoChem Biosciences Inc
  • Naicons Srl
  • Oragenics Inc
  • Rebiotix Inc
  • MORE
I. Key Findings

1. Companies Investing in Vancomycin Resistant Enterococcal (VRE) Infection Pipeline include-
Number of Companies with Vancomycin Resistant Enterococcal (VRE) Infection projects in pre-clinical Development-
Number of Companies with Vancomycin Resistant Enterococcal (VRE) Infection projects in Clinical Development-
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Americas
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Europe
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Asia Pacific
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Agents in Clinical Development stage
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Vancomycin Resistant Enterococcal (VRE) Infection Pipeline agents

II. Insights into Vancomycin Resistant Enterococcal (VRE) Infection Pipeline

1. Disease Overview
Introduction to Vancomycin Resistant Enterococcal (VRE) Infection
Symptoms and Causes of Vancomycin Resistant Enterococcal (VRE) Infection
Treatment or Prevention Options for Vancomycin Resistant Enterococcal (VRE) Infection
Other Details
2. Phase wise Pipeline Compounds
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Phase 1 stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Phase 2 stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Phase 3 stage Drugs
Vancomycin Resistant Enterococcal (VRE) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Compounds
4. Vancomycin Resistant Enterococcal (VRE) Infection Pipeline by Mechanism of Action

III. Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Compound Details
  • Marinus
  • antibiotics for Vancomycin Resistant Enterococci Infections
  • AZX1103
  • HB1345
  • LCB01-0371
  • MGB-BP3
  • contezolid
  • NAI-107
  • NAI-603
  • Teixobactin
  • BDM-I
  • OG716
  • antibiotic molecule for Vancomycin Resistant Enterococcus Infections
  • RBX2660
  • SLP-0901
  • SLP-0905
  • AM 218
  • WCK 5222
Drug Details

1. Snapshot-
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Company Briefs
  • Aphios Corporation
  • Arietis Corporation
  • AzurRx BioPharma Inc
  • Helix BioMedix Inc
  • LegoChem Biosciences Inc
  • MGB Biopharma Ltd
  • MicuRx Pharmaceuticals Inc
  • Naicons Srl
  • NovoBiotic Pharmaceuticals LLC
  • Opal Biosciences Ltd
  • Oragenics Inc
  • Ovensa Inc
  • Rebiotix Inc
  • Sealife PHARMA GMBH
  • Sinsa Labs Inc
  • Wockhardt Ltd
V. Latest News and Developments in Global Vancomycin Resistant Enterococcal (VRE) Infection Pipeline Market

VI. Appendix
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aphios Corporation
  • Arietis Corporation
  • AzurRx BioPharma Inc
  • Helix BioMedix Inc
  • LegoChem Biosciences Inc
  • MGB Biopharma Ltd
  • MicuRx Pharmaceuticals Inc
  • Naicons Srl
  • NovoBiotic Pharmaceuticals LLC
  • Opal Biosciences Ltd
  • Oragenics Inc
  • Ovensa Inc
  • Rebiotix Inc
  • Sealife PHARMA GMBH
  • Sinsa Labs Inc
  • Wockhardt Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll